Can-Fite BioPharma
Israeli clinical-stage biopharmaceutical company developing adenosine receptor-based therapies for cancer and inflammatory diseases
Take Action
Apply pressure where it matters. Use these tools and personalise your message with evidence from this page.
- Contact Investor RelationsContact investor relations regarding corporate governance concerns
- Report New IntelligenceSubmit evidence of contracts, partnerships, or developments
- Share This ProfileReady-written posts for LinkedIn, X, Bluesky, Instagram, Facebook and WhatsApp, with this company's share card
- View Strategic AnalysisIn-depth analysis and engagement strategy
Before taking action, review our Code of Conduct for professional standards and ethical guidelines.
Help Us Hold Can-Fite BioPharma Accountable
Your skills and knowledge can strengthen this campaign. Join our volunteer research team or share insider information securely.
Leverage Your Expertise
Do you work in this sector? We need professionals who understand procurement cycles, regulatory compliance, and corporate governance. Don't just boycott - lead!
Decision-Maker Directory
Key individuals with influence over corporate partnerships and procurement decisions. The contact details shown are published business addresses, listed for professional correspondence only. Write to the role, not the person, and keep correspondence courteous and factual. Repeated, abusive or personal contact is unlawful harassment and damages the case being made.
Material Risk Framing
Frame your message around business risks. These talking points resonate with corporate stakeholders and institutional investors.
Pre-commercial biotech with no marketed products; minimal direct regulatory exposure beyond clinical trial compliance
Significant financial distress with history of dilutive offerings and reverse stock splits; Altman Z-Score indicates bankruptcy risk
Low public visibility as clinical-stage company; B2B focus limits consumer pressure effectiveness
No commercial products currently; clinical trials represent primary operational exposure
Strategic Analysis
In-depth assessment of the company's position, vulnerabilities, and recommended approaches for effective engagement.
Lower severity, lower vulnerability: watch list, gather intel
- Severity
- 4.5/10
- Strategic vulnerability
- 3.0/10
Learn about our methodology. Companies are categorised based on severity (harm potential) vs strategic vulnerability (campaign leverage).
Why do these scores change?
Unlike static boycott lists, our targeting model is dynamic. This company's position on the matrix is re-evaluated continually as we verify new contracts, divestments, or policy changes. Your reporting directly impacts this score.
Can-Fite BioPharma is a clinical-stage Israeli biopharmaceutical company representing a lower-priority boycott target within the pharmaceutical sector. Founded in 1994 and headquartered in Petah Tikva, Israel, the company has no commercially marketed products and limited economic footprint compared to established pharmaceutical companies like Teva. The company's primary strategic relevance lies in its Israeli headquarters, dual stock exchange listing, and contribution to Israel's biotech ecosystem.
Key Leverage Points
- Financial Vulnerability: Severe financial distress with 1-for-3,000 reverse stock split, negative Altman Z-Score, and ongoing capital requirements create investor pressure points
- Pre-Commercial Status: No marketed products means no consumer boycott opportunity; focus on institutional investor engagement
- Dual Listing: NYSE American and TASE listings enable engagement with both US and Israeli institutional investors on ESG grounds
- Small Employee Base: Approximately 9 employees limits direct economic impact but concentrates decision-making
Evidence Summary
Can-Fite's financial history demonstrates significant challenges typical of clinical-stage biotech. The company has raised $175 million cumulatively for drug development but continues to operate at substantial losses (operating margin of approximately -1,595%). The December 2025 announcement of a 1-for-3,000 reverse stock split - among the most severe in biotech history - reflects extensive shareholder dilution. The company's Altman Z-Score places it in the distress zone, indicating bankruptcy risk. Lead drug candidates piclidenoson and namodenoson are in Phase 3 trials for psoriasis and liver cancer respectively, with FDA Orphan Drug and Fast Track designations for namodenoson.
Engagement Strategy
Given Can-Fite's pre-commercial status and limited economic impact, this company should be monitored rather than actively targeted. Institutional investors considering biotech investments should be informed of the company's Israeli headquarters and contribution to Israel's economy as part of ESG due diligence. The company's financial vulnerability may make it responsive to investor concerns. Focus resources on higher-impact pharmaceutical targets like Teva, which has substantial commercial operations and market presence. Can-Fite's potential commercialisation of drug candidates (expected post-2026) would warrant reassessment of priority status.
Evidence & Sources
Verified sources including NGO reports, regulatory filings, and primary documents. Use these to substantiate your correspondence. Entries marked First-hand were reported directly to this site and are published without identifying the source.
23 Dec 2025 Corporate Statement Can-Fite Announces 1-for-3,000 Reverse Stock Split
Company announced significant reverse stock split effective January 2026, reducing authorised shares from 42 billion to 14 million, indicating severe dilution history
Open source28 Aug 2025 Corporate Statement Can-Fite Reports H1 2025 Financial Results and Clinical Update
Financial results confirming clinical-stage status with ongoing losses and capital requirements
Open source1 May 2025 Corporate Statement Can-Fite Has Raised $175 Million in Total Funding to Date
Confirms cumulative fundraising for Namodenoson and Piclidenoson development, advancing into Phase 3 trials
Open source24 Mar 2025 Official Doc Can-Fite Initiates Pivotal Phase 3 Psoriasis Study
FDA and EMA-approved protocol for piclidenoson Phase 3 trial in moderate to severe plaque psoriasis
Open source1 Jan 2024 Filing NYSE American Listing - CANF
Dual-listed on NYSE American and Tel Aviv Stock Exchange; American Depositary Shares represent ordinary shares
Open sourceUpdates & Milestones
Board approved significant reverse stock split reflecting severe historical dilution; effective January 2026
Advanced Piclidenoson (psoriasis) and Namodenoson (liver cancer) into pivotal Phase 3 studies
Namodenoson receives Orphan Drug Designation for hepatocellular carcinoma in US and Europe
Listed on NYSE American (formerly AMEX) as ADRs, enabling US investor access
Renamed to Can-Fite BioPharma Ltd. to reflect biopharmaceutical focus
Established as Can-Fite Technologies Ltd. in Israel, developing adenosine receptor platform technology